|
|||||
|
|
The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model |
|
| Authors: | Masa-Aki Shibata Jayakrishna Ambati Eiko Shibata Romulo JC Albuquerque Junji Morimoto Yuko Ito Yoshinori Otsuki |
| Affiliation: | (1) Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, Osaka, Japan;(2) Department of Ophthalmology and Visual Sciences and Physiology, University of Kentucky, Lexington, KY, USA;(3) Laboratory for Drug Discovery Innovation, Department of Molecular Pharmacology, National Cerebral & Cardiovascular Center Research Institute, Osaka, Japan;(4) Laboratory Animal Center, Osaka Medical College, Osaka, Japan |
| Abstract: | BackgroundCancer metastasis contributes significantly to cancer mortality and is facilitated by lymphangiogenesis and angiogenesis. A new splicing variant, endogenous soluble vascular endothelial growth factor receptor-2 (esVEGFR-2) that we recently identified is an endogenous selective inhibitor of lymphangiogenesis. To evaluate the antimetastatic potential of esVEGFR-2, gene therapy with vector expressing esVEGFR-2 (pesVEGFR-2) or endostatin (pEndo) as a positive control was conducted on murine metastatic mammary cancer. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |